Back to search
FDAFDA · Food and drugs·Recall number D-0229-2015

CUBICIN (daptomycin for injection) 500 mg, For Intravenous Use Only, Rx Only, Single use Vial, Manufactured for: Cubist Pharmaceuticals Inc., Lexington, MA 02421, USA, NDC 67919-011-01

Published November 5, 2014 · Recall initiated: August 8, 2014

Summary

FDA records drug Class I recall D-0229-2015, published November 5, 2014 and initiated August 8, 2014. Recalling firm: Cubist Pharmaceuticals, Inc.; Status: Terminated; Reported quantity: 371,879 Vials; Lot: Lot #'s: CDC203, Exp 12/2015; CDC207, Exp 01/2016; CDC213, Exp 02/2016; CDC217, Exp 03/2016; CDC226, Exp 04/2016; CDC234, CDC235, Exp 05/2016; CDC243, CDC246, Exp 07/2016. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Particulate Matter: Foreign particulate matter (tiny black specs) were observed at the bottom of the vial following reconstitution.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Cubist Pharmaceuticals, Inc.
Distributor
Nationwide and Puerto Rico.
Lot
Lot #'s: CDC203, Exp 12/2015; CDC207, Exp 01/2016; CDC213, Exp 02/2016; CDC217, Exp 03/2016; CDC226, Exp 04/2016; CDC234, CDC235, Exp 05/2016; CDC243, CDC246, Exp 07/2016.
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was CUBICIN (daptomycin for injection) 500 mg, For Intravenous Use Only, Rx Only, Single use Vial, Manufactured for: Cubist Pharmaceuticals Inc., Lexington, MA 02421, USA, NDC 67919-011-01 recalled?

Yes. FDA published recall D-0229-2015 on November 5, 2014. Reported hazard: Presence of Particulate Matter: Foreign particulate matter (tiny black specs) were observed at the bottom of the vial following reconstitution.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release